Polaris Group announced dosing of first patient in phase 2 trial of ADI-PEG 20 with radiation and TMZ in patients with GBM. Polaris Group announced that the first patient was dosed with ADI-PEG 20 in the Phase II clinical trial for Glioblastoma Multiforme (GBM) at Chang Gung Memorial Hospital, Linkou, Taiwan. This Phase II clinical trial is a placebo-controlled, randomized, and double-blind study, using company's novel metabolic therapy drug, ADI-PEG 20, in combination with radiation therapy and chemotherapy drug TMZ (Temozolomide).

The trial is conducted in multiple countries and centers, including Taiwan and South Korea, with an anticipated enrollment of 100 patients. The primary endpoint is Overall Survival, and secondary endpoint is Progression-Free Survival (PFS). The principial Investigator for this clinical trial is Professor Wei Kuo-Chen from Chang Gung Hospital, Linkou, Taiwan.

The trial is being led by Taiwanese physicians and involves international participation, which reflects recognition of Taiwan's medical capabilities and is expected to provide greater opportunities for Taiwanese hospitals in the field of new drug clinical trials. ADI-PEG 20, developed by Polaris Group, operates through a unique mechanism of action. It utilizes metabolic therapy to degrade arginine in the blood and can be combined with other cancer treatment modalities to produce synergistic effects.